Reading Time: < 1 minuteI’m glad to finally announce that UK recruitment for the dexpramipexole clinical trial is now open! So far, we are aware that Liverpool has opened
Category: Treatments
Reading Time: 2 minutesWe have been made aware that there’s a new kid on the block in terms of unproven treatments, which is a new route of administration
Reading Time: < 1 minuteWe’re aware that thing’s may seem quiet in terms of ‘big’ MND research moments… almost too quiet… Well, today, the pharmaceutical companies Biogen Idec and Knopp Biosciences announced
Reading Time: 2 minutesAn unproven treatment called ‘Spirulina’, which is a type of blue-green algae, has recently been investigated by ALSUntangled*. They concluded that there is no evidence
Reading Time: 2 minutesThe room was crowded at 8am for the first presentation of day two, from Dr Doug Sipp (RIKEN Institute, Japan) on ‘Unregulated ALS/MND treatments and public education’. Dr
Reading Time: 2 minutesOne human neural stem cell line that has cleared the US Government’s regulatory hurdles is that developed by the biotechnology company Neuralstem. To date, nine
Reading Time: 2 minutesThe remainder of the morning covered some of the preclinical research that has laid the foundations for current and forthcoming clinicalstudies. Prof Clive Svendsen, from University Wisconsin-Madison, gave an
Reading Time: 2 minutesThis year, two sessions are related to clinical trials. The first, concerns the planning and design of clinical trials. The second is the results of
Reading Time: < 1 minuteSharing information at the symposium is what it’s all about. Today, Randall Kaye, chief medical officer from Avanir Pharmaceuticals, chose the symposium to give a presentation on
Reading Time: 2 minutesLast weekend 19 neurologists and researchers gathered in a hotel seminar room in The Netherlands to talk about building closer links across Europe. Prof Leonard